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Drug-induced interstitial lung disease is associated with signiﬁcant morbidity and mortality. Everolimus
is an inhibitor of mTOR, a mammalian target of rapamycin, used as an immunosuppressant agent in solid
organ transplant. Everolimus has been associated with interstitial lung disease in solid organ transplant
patients but has been rarely reported in the liver transplant patient population. We report a case of
interstitial pneumonitis in a liver transplant patient associated with everolimus which completely
resolved after discontinuation of the medication.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Drug-induced pulmonary toxicity is not uncommon and
immunosuppressive drugs have been associated with interstitial
lung disease. Early diagnosis and treatment can potentially improve
outcomes. Mammalian target of rapamycin (mTOR) inhibitors,
sirolimus and everolimus, are used as immunosuppressive agents
in solid organ transplant recipients and as anti-neoplastic agents.
Common side effects of everolimus include stomatitis, rash, and
fatigue. Everolimus has also been associated with noninfectious
interstitial pneumonitis. However, there are only two reports of
everolimus-induced noninfectious interstitial pneumonitis
described in liver transplant patients.2. Case report
A 60 year old female with medical problems signiﬁcant for
diabetes mellitus type II (insulin-dependent poorly controlled),
hypertension, chronic kidney disease stage III, anemia of chronic
disease, hypothyroidism, liver cirrhosis secondary to nonalcoholic
fatty liver disease (NAFLD) and hepatocellular carcinoma under-
went liver transplant one year prior to presentation. She presented
to the emergency department with intermittent fever for three
months associated with cough and shortness of breath. Herrg (A.S. Siddiqui).
Ltd. This is an open access article umedications included amlodipine, levothyroxine, insulin detemir,
and insulin aspart with meals. Her chronic immunosuppressive
treatment included everolimus 10 mg daily and prednisone 5 mg
daily. On physical examination, she had a temperature of 100.8 F,
initial oxyhemoglobin saturation 93% on room air, blood pressure
130/80 mm Hg and heart rate 72/min. Chest auscultation revealed
diminished breath sounds in the right base. The rest of the physical
examination was unremarkable. The white blood cell count was
4.6  10*3 U/L. Blood chemistries were normal. Blood, sputum and
urine cultures were negative. HIV1 and HIV2 antibodies (enzyme
immunoassay), serum histoplasmosis antigen and antibodies, urine
histoplasmosis antigen, serum coccidioidomycosis antibodies (IgM,
IgG) were negative. Epstein- Barr virus PCR and cytomegalovirus
PCR were negative. Viral hepatitis studies were also negative.
Everolimus level was 4.3 ng/ml (Normal therapeutic range e
5e20 ng/ml). Chest radiograph showed patchy bibasilar interstitial
inﬁltrates [Fig. 1]. Computed tomography (CT) scan of the chest
showed diffuse patchy ground glass opacities throughout the lungs
[Fig. 2].
The patient was started empirically on vancomycin, ceﬁpime
and ﬂuconazole for possible infection. She continued to have fever
and cough after seven days of antibiotic treatment. Bronchoscopy
with bronchoalveolar lavage (BAL) and transbronchial biopsy were
performed. BAL ﬂuid analysis showed predominant lymphocytes.
BAL cultures including acid fast bacillus (AFB) stain and cultures
were negative. In the setting of persistent symptoms and negative
diagnostic workup, drug-induced interstitial pneumonitis was
considered, and all the medications were carefully reviewed.nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Chest radiograph showing patchy bibasilar interstitial inﬁltrates.
Fig. 2. Computed tomography (CT) scan of the chest showing diffuse patchy ground
glass opacities.
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described in literature, therefore everolimus was discontinued as a
therapeutic intervention. The patient was started on tacrolimus for
immunosuppression. Her symptoms gradually improved and at 3
months follow up, she had complete resolution of clinical symp-
toms along with complete resolution of interstitial inﬁltrates on CT
scan [Fig. 3].Fig. 3. Computed tomography (CT) scan of the chest sowing complete resolution of
interstitial inﬁltrates at three months follow up.3. Discussion
Everolimus is a selective inhibitor of the mammalian target of
rapamycin (mTOR), a central regulator of intracellular signaling
pathways involved in cell growth and proliferation, cellular meta-
bolism and angiogenesis. Everolimus is used as an immunosup-
pressant in solid organ transplant patients [1]. Interstitial
pneumonitis is associated with everolimus and has been reported
in literature with similar presentation as described in our case
[2e11]. The exact pathogenesis of the lung toxicity cause by mTOR
inhibitors is not clear. A proposed mechanism includes interaction
with the STAT1 (Signal Transducer and Activator of Transcription 1)
gene, which may amplify cellular apoptosis and can increase lung
injury. STAT1 augments LPS (lipopolysaccharides) and IFN-b
(Interferon b) causing apoptosis and pulmonary vascular leak
[12]. Clinical presentation includes cough, shortness of breath, fever
and hypoxemic respiratory failure. Diffuse alveolar hemorrhage has
also been attributed to everolimus [13]. Radiographic patterns vary
from ground glass inﬁltrates to diffuse interstitial inﬁltrates.
Treatment of everolimus-induced pneumonitis is early discontin-
uation of the drug. Corticosteroids have been used to treat patients
with severe pneumonitis [14]. We did not use corticosteroids for
the treatment of interstitial pneumonitis because of moderate
symptoms, stable oxygenation and gas exchange in our patient.
Furthermore, there is no clear evidence to support use of steroids
for mTOR inhibitor-induced pulmonary toxicity. Two cases of
everolimus-induced pneumonitis in liver transplant patients have
been previously described [15,16]. To the best of our knowledge,
this is the third case of everolimus-induced interstitial pneumonitis
in liver transplant patients. In the previously reported case by
Schrader et al., the patient had localized left lower lobe inﬁltrates,
and follow up CT scan of chest onemonth after stopping everolimus
did not show complete resolution of the inﬁltrates. Our patient had
diffuse patchy ground glass inﬁltrates more suggestive of a drug-
induced mechanism and also showed complete resolution of clin-
ical symptoms and pulmonary inﬁltrates after discontinuation of
everolimus at three months follow up. In the case reported by
Marín-Gomez et al., everolimus was never completely discontinued
and follow up imaging did not result in complete resolution of in-
ﬁltrates. Furthermore everolimus levels were signiﬁcantly higher in
this case. The patient in our case had normal levels of everolimus.
Our case report highlights a rare case of interstitial pneumonitis
associated with normal levels of everolimus in a liver transplant
patient. Furthermore it emphasizes that interstitial pneumonitis is
a class effect of mammalian target of rapamycin inhibitors and not
limited to sirolimus. One limitation of our case includes the lack of
rechallengewith everolimus, but we did not rechallenge because of
potential morbidity and mortality associated with recurrence of
disease.
Clinicians need to have a high suspicion for drug-induced
toxicity in liver transplant patients on immunosuppression with
everolimus who present with respiratory symptoms. Key features
that support the diagnosis are characteristic interstitial pneumo-
nitis on imaging and a negative work up for infection. We suggest
discontinuation of everolimus for the treatment of everolimus
induced interstitial pneumonitis but corticosteroids may be
considered for severe life threatening disease. Early recognition of
everolimus toxicity and appropriate discontinuation can prevent
signiﬁcant morbidity and adverse outcomes.
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